Evidence map›Paper›PMID 38476326›Full record

ArticleFrontiers in pharmacology2024

Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease.

Qing-Wei Ma, Rui-Ting Han, Zi-Jie Wu, Jun-Jie Zhou, Meng-Ting Chen, Xiang-Zhi Zhang, Wen-Zhe Ma, Na Feng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Qing-Wei Ma *School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Rui-Ting Han *School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Zi-Jie WuSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Jun-Jie ZhouSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Meng-Ting ChenSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Xiang-Zhi ZhangSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Wen-Zhe MaState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, China.
Na FengSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Wuyi University · CNMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both continuous oxidative stress and poly (ADP-ribose) polymerase 1 (PARP-1) activation occur in neurodegenerative diseases such as Parkinson's disease. PARP-1 inhibition can reverse mitochondrial damage and has a neuroprotective effect. In a previous study, we synthesized melatonin derivative 6a (MD6a) and reported that it has excellent antioxidant activity and significantly reduces α-synuclein aggregation in

Indexed as

melatonin derivativemitochondrial dysfunctionmTORParkinson’s diseasePARP-1

Identifiers

PMID38476326
PMCPMC10927953
OpenAlexW4392195370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.